All Search Results
-
No more heading in youth soccer, but is this enough to keep kids safe?
Concussions are a hot topic these days, and for good reason.
-
Is 36 seconds enough time to talk about sex?
A new study published in JAMA Pediatrics shows that doctors are spending an average of 36 seconds talking to teenagers about sex, that is if they talk about it at all. One-third of teenagers receiving a yearly check-up didn’t have any mention of sexual health or development.
-
Four things to know about concussions in kids
Concussions happen all the time. According to the American Academy of Pediatrics, an estimated 3.8 million recreation and sports-related concussions occur in the US each year! And as brain injuries, every concussion needs to be taken seriously. Research is ongoing into the long-term effects of traumatic brain damage in both youth and adults, but in the meantime, here are some things you should you know about the injury and its implications for your child returning to school and play.
-
Orlando Health ER and Medical Pavilion - Osceola
The Orlando Health emergency room and medical pavilion will be designed to meet both current and future needs of this growing community.
-
CIBMTR Research Database
Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
-
Beat Childhood Cancer Specimen Banking and Data Registry
Specimen Banking With Clinical and Genomic Data Registry With the Establishment of Tumor Models for Pediatric Cancers
-
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma
-
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
-
Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB)
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
-
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥1 to <31 Years Old With First Relapse
